Genscript Biotech
Genscript Biotech Corporation, commonly referred to as Genscript, is a leading biotechnology company headquartered in the United States. Founded in 2002, Genscript has established itself as a pioneer in the fields of gene synthesis, peptide synthesis, and antibody development, serving a diverse range of industries including pharmaceuticals, academia, and diagnostics. With major operational regions across North America, Europe, and Asia, Genscript offers a comprehensive suite of services that includes custom gene and protein production, CRISPR gene editing, and molecular biology tools. The company is renowned for its innovative approach and high-quality products, which have positioned it as a trusted partner in the global biotech landscape. Genscript's commitment to advancing scientific research has led to numerous accolades, solidifying its reputation as a key player in the biotechnology sector.
DitchCarbon Score
How does Genscript Biotech's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Genscript Biotech's score of 8 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Genscript Biotech's reported carbon emissions
In 2023, GenScript Biotech reported total carbon emissions of approximately 97,949,660 kg CO2e, comprising about 12,090,920 kg CO2e from Scope 1 and about 85,858,740 kg CO2e from Scope 2 emissions. This represents a significant increase in emissions compared to previous years, with 2019 emissions recorded at approximately 48,371,130 kg CO2e for Scope 1 and about 44,105,720 kg CO2e for Scope 2. GenScript Biotech has committed to achieving net-zero emissions by 2050, as part of its long-term climate strategy. This commitment encompasses all scopes of emissions, indicating a comprehensive approach to reducing its carbon footprint. The company is currently in the process of implementing its near-term targets, having officially committed to the Science Based Targets initiative (SBTi) as of April 2024. Overall, GenScript Biotech's emissions data highlights the challenges faced in reducing carbon output while scaling operations, alongside its proactive stance towards long-term sustainability goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2017 | 2018 | 2019 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 1,752,700 | 0,000,000 | 0,000,000 | 00,000,000 |
| Scope 2 | 13,782,800 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Genscript Biotech is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
